Gestational Diabetes
Pipeline by Development Stage
Metabolic Diseases is a $70.5B mature market dominated by diabetes and anticoagulation therapies with sustained blockbuster momentum.
Key Trends
- GLP-1 agonists (Ozempic, Mounjaro) driving explosive growth and market consolidation
- SGLT2 inhibitors expanding beyond diabetes into cardio-renal indications
- Significant patent cliff risk 2027-2029 for DPP-4 inhibitors (Januvia) and older insulins
Career Verdict
Excellent opportunity for specialists seeking stable, high-revenue exposure with strong hiring momentum in commercial and engineering roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 26% | Launch | Stable | 15.0yr |
| 2 | OZEMPIC (semaglutide) | Novo Nordisk | $9.2B | 13% | Peak | Growing | 12.4yr |
| 3 | JARDIANCE (empagliflozin) | Boehringer Ingelheim | $8.8B | 12% | Peak | Growing | 8.6yr |
| 4 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 10% | Peak | Stable | |
| 5 | FARXIGA (dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
Drug Class Breakdown
stable, mature franchise
rapid growth, expanding indications
growing, cardio-renal expansion
stable, generics pressure
declining, patent cliff 2027
Career Outlook
GrowingMetabolic diseases offers stable, high-value career trajectory with blockbuster product revenue supporting competitive compensation and long-term job security. Commercial and field-based roles dominate hiring, reflecting the shift toward patient access, digital health, and device integration in diabetes management. Patent cliff exposure in DPP-4 class (2027-2029) creates near-term volatility for Merck but limited impact on overall market given GLP-1 dominance.
Breaking In
Target device companies (Insulet, Abbott) or diagnostic firms for entry-level roles if traditional pharma hiring is limited; strong foundation in diabetes biology and HbA1c/CGM metrics will accelerate credibility.
For Experienced Professionals
Experienced professionals should prioritize GLP-1 franchise or SGLT2 indication expansion roles; avoid Merck DPP-4-focused assignments given 2027 patent cliff, unless willing to transition to next-generation pipeline.
In-Demand Skills
Best For
Hiring Landscape
Hiring activity is concentrated in commercial roles (166 positions) and engineering (126 positions), driven by device makers (Insulet: 270 jobs) and diagnostic companies (Abbott: 154 jobs) rather than traditional pharma. Sanofi leads pharma hiring with 42 metabolic-focused positions, but specialized roles in clinical operations remain constrained. Salary expectations range from $153K (Clinical Ops) to $274K (Manufacturing), with strong compensation for commercial and quality roles.
Top Hiring Companies
By Department
Strongest hiring momentum in device/delivery and commercial infrastructure; traditional pharma R&D roles remain limited despite blockbuster pipeline.
Competitive Landscape
20 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 29 trials with date data
Clinical Trials (29)
Total enrollment: 40,737 patients across 29 trials
Gestational Diabetes and Pharmacotherapy (GAP)
Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
DETERMINE: Detemir vs NPH
Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness
Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot
Artificial Intelligence and Gestacional Diabetes
Patterns and Glycaemic Endpoints for Diagnosing Gestational Diabetes
To Identify Urinary Biomarkers Associated With Gestational Diabetes Mellitus [GDM]
Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy
Postpartum Continuous Glucose Monitoring (CGM) Study
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)
A Study on the Use of Real -Time Continuous Glucose Monitoring (RT-CGM) in Gestational Diabetes
Exercise in Pregnant Women With Gestational Diabetes
Time-in-range Using Continuous Glucose Monitoring Management of Gestational Diabetes Mellitus
Weight Gain Recommendations for Chinese Women With Gestational Diabetes Mellitus
Shared Decision Making in Diabetes Prevention for Women With a History of GDM
Real-time Continuous Glucose Monitoring
Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes
Gut and Oral Microbiome of GDM Patients During Pregnancy
Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)
Randomizing Two Gestational Diabetes Screening Methods in a Diverse HMO
The Belgian Diabetes in Pregnancy Study: BEDIP-N Study
Early Gestational Diabetes Screening in the Gravid Obese Woman
Gestational Diabetes
Magnesium Supplementation in the Second Trimester of Pregnancy to Overweight and Obese Individuals
Breast Milk Hormones and Early Infant Growth of Women With Gestational Diabetes Mellitus
Testing Ascensia Contour Glucometer for the Measurement of Blood Glucose
Related Jobs in Metabolic Diseases
Associate Director, SEC Reporting & Technical Accounting
Head of Manufacturing
Clinical Diabetes Specialist - New Haven
Territory Business Leader - Columbia SC
Territory Business Leader - Seattle
Territory Business Leader- Phoenix North
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.